Wegovy (semaglutide) Injector 0.25 mg/0.5 mL, 4 Pens Per Box **Refrigerated Item**

Wegovy (semaglutide) Injector is a prescription medication used to treat obesity in adults who have a body mass index (BMI) of 30 kg/m² or greater, or in adults with a BMI of 27 kg/m² or greater who also have at least one weight-related medical condition, such as high blood pressure, type 2 diabetes, or high cholesterol. It contains the active drug semaglutide, which is a glucagon-like peptide-1 (GLP-1) receptor agonist that helps to decrease appetite and increase feelings of fullness, thereby aiding in weight loss. The injector is a prefilled pen device that is used to inject the medication under the skin once a week.

Wegovy Semaglutide) injection is an injectable prescription medication for adults with obesity (BMI ≥30) or overweight (excess weight) (BMI ≥27) who also have weight-related medical problems, to help them lose weight and keep it off.

Wegovy (semaglutide) Injector 0.25 mg/0.5 mL is used to treat adults with obesity and those who are overweight and facing with increased obesity-related health problems. It is used together with other weight loss solutions to reduce body weight around 3% from the baseline body weight. Wegovy works as Glucagon-like-peptide 1 receptor agonist, as it increases the feeling of fullness and limits the intestinal absorption of fat. Wegovy is available as a prefilled, disposable dose pen. It contains 0.25mg/0.5mL of semaglutide, making it is easy and convenient to take with measuring instructions provided. Wegovy is efficient and effective constraining certain therapies specified before mealtime, such as reducing energy intake. Increases in physical exercise with Wegovy significantly promotes weight loss and well-being, which makes it useful battling against obesity. Wegovy has detailed dosing program that broadly involves one daily self-injection of either 0.25mg or 0.5mg dosage solution. Wegovy has been found to be safe and effective in the long term, in a large scale of participants with varied demographic profiles.

In clinical trials, Wegovy was shown to reduce body weight in people with body mass indexes, or BMIs, of 27 or greater by around 15% over 68 weeks. People on average lost about an eighth of that weight in the first month